Laronidase

DRUG11 trials

Conditions

Cognitive DeclineHurler SyndromeHurler's SyndromeHurler-Scheie SyndromeLysosomal Storage DiseaseLysosomal Storage DiseasesMPS IMucopolysaccharidosis I

Phase 1

Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

TerminatedNCT00215527

Patricia I. Dickson, M.D.Lysosomal Storage Diseases, Mucopolysaccharidosis I, Spinal Cord Compression

Start: 2005-11-30End: 2011-10-31Updated: 2013-02-21

Immune Tolerance Study With Aldurazyme® (Laronidase)

CompletedNCT00741338

Genzyme, a Sanofi CompanyMucopolysaccharidosis I

Start: 2008-09-30End: 2012-09-30Updated: 2014-07-02

Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

TerminatedNCT00786968

Patricia I. Dickson, M.D.Hurler-Scheie Syndrome, Lysosomal Storage Disease, Mucopolysaccharidosis I +2

Start: 2008-01-31End: 2011-10-31Updated: 2013-02-21

Administration of IV Laronidase Post Bone Marrow Transplant in Hurler

CompletedNCT01173016

Masonic Cancer Center, University of MinnesotaHurler Syndrome

Start: 2012-05-29End: 2016-03-04Updated: 2020-03-20

Phase 3

A multi-center, randomized, active controlled clinical trial to evaluate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared to standard of care with allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Active, not recruitingCTIS2022-500306-17-00

Orchard Therapeutics (Europe) LimitedHurler Syndrome, Mucopolysaccharidosis type I

Start: 2024-09-20Target: 11Updated: 2025-07-25

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

CompletedNCT06406153

CinnagenMucopolysaccharidosis Type 1

Start: 2022-09-10End: 2023-11-18Updated: 2024-08-06

Phase 4

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

CompletedNCT00144768

Genzyme, a Sanofi CompanyHurler-Scheie Syndrome, Hurler's Syndrome, Mucopolysaccharidosis I +1

Start: 2004-07-31End: 2007-05-31Target: 25Updated: 2014-05-05

A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

TerminatedNCT00418821

Genzyme, a Sanofi CompanyHurler-Scheie Syndrome, Hurler's Syndrome, Mucopolysaccharidosis I +1

Start: 2010-10-22End: 2022-12-21Updated: 2024-02-20

China Post-marketing Surveillance (PMS) Study of Aldurazyme®

CompletedNCT05134571

Genzyme, a Sanofi CompanyMucopolysaccharidosis I

Start: 2021-10-28End: 2023-07-26Updated: 2025-09-17

Unknown Phase

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

CompletedNCT00852358

Patricia I. Dickson, M.D.Cognitive Decline, Hurler-Scheie Syndrome, Lysosomal Storage Disease +2

Start: 2009-06-30End: 2015-04-30Updated: 2016-01-26

Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome

TerminatedNCT01572636

Masonic Cancer Center, University of MinnesotaHurler Syndrome, MPS I, Mucopolysaccharidosis Type IH

Start: 2012-03-28End: 2018-05-01Updated: 2018-09-27

Related Papers

Safety and efficacy of laronidase in Chinese patients with mucopolysaccharidosis type I: a phase IV, single-arm, open-label, multicenter study.

2025-10-29

Efficacy and safety of a biosimilar laronidase versus the reference laronidase in patients with mucopolysaccharidosis type I.

2025-08-19

Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes.

2019-10-017 citations

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I.

2017-01-1312 citations

Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement therapy

Clinical and Experimental Obstetrics & Gynecology2015-02-1015 citations